Cardiovascular and liver care gaps

A new review argues that metabolic dysfunction-associated steatotic liver disease, often called MASLD, needs to be assessed alongside cardiovascular disease. The authors describe connected metabolic and inflammatory pathways. They also say access to diagnosis and fibrosis assessment can differ sharply between groups, as can insurance coverage and continuing care. The paper includes semaglutide among treatment options for selected adults with metabolic dysfunction-associated steatohepatitis, or MASH, but it does not show that access gaps have been solved^[1].

The review was published in Current Cardiology Reports on 3 October 2026. It is a review article. It did not assign people to semaglutide, another medicine, or usual care. Its main contribution is a framework for reading cardiovascular and liver risk alongside the practical barriers that can shape who is recognised, assessed, and treated^[2].

MASLD and cardiovascular disease overlap

MASLD is a chronic liver disease associated with metabolic dysfunction. This review describes it as a multisystem cardiometabolic disorder rather than a liver problem that can be considered in isolation. Cardiovascular disease is a major source of illness and death in this population. Obesity and type 2 diabetes sit within the shared clinical picture, as do hypertension and cardiovascular disease^[1].

That overlap does not mean every person with liver disease has the same cardiovascular risk. One result cannot stand in for a full assessment. The paper calls for early risk identification and individualised cardiovascular prevention. It also places noninvasive fibrosis assessment in a stepwise approach. Fibrosis means scarring in the liver; noninvasive assessment refers to methods that do not require a liver biopsy^[1].

For readers who have encountered semaglutide in this context, our semaglutide guide explains the medicine class in plain language. A medicine's appearance in a review of MASH care does not turn it into a universal treatment for liver disease or cardiovascular disease. Eligibility, risks, and follow-up remain clinical questions that need individual assessment.

What the review means by disparities

Authors caution against treating measured differences in disease prevalence across racial and ethnic groups as a simple genetic story. Those differences need to be interpreted alongside structural inequities and diagnostic practices, with access to care considered separately. Socioeconomic disadvantage may also affect diagnosis and treatment. Barriers related to sex and gender may do so as well^[1].

This is an evidence boundary worth keeping clear. The review does not provide a single biological explanation for differences between groups. It says prevalence measures have to be read in context. Nor does it establish that one screening pathway will remove disparities. A medicine or insurance policy alone cannot be assumed to do that. The article instead identifies several parts of care where unequal access may limit the benefit of available options^[2].

A cardio-hepatology approach means coordinating cardiovascular and liver care rather than splitting those questions between disconnected visits. The authors propose an equity-centered version. Their framework starts with early risk identification and stepwise fibrosis assessment. It also includes individualised cardiovascular prevention plus access to indicated liver-directed therapies^[1].

Where semaglutide fits in the paper

The review states that resmetirom and semaglutide have expanded treatment options for selected adults with MASH. The careful words are selected adults and treatment options. The abstract does not give a dosing plan. It does not compare outcomes between medicines or recommend that readers start, stop, or switch a treatment. Unequal access to fibrosis assessment may limit who benefits. Insurance coverage and longitudinal care may also do so^[1].

Longitudinal care means follow-up over time. That detail matters because a prescription alone does not answer whether someone can complete assessment, obtain coverage, monitor other conditions, or continue treatment. Readers can use our semaglutide regulation overview for background on regulatory status, while a treating clinician can explain whether any approved use applies to an individual's circumstances.

The article also argues that treatment and quality measures should reflect clinical eligibility rather than medication use alone. A lower medicine-use figure cannot automatically be read as lower need or poorer care. It also cannot prove better care or a patient preference. The review frames medication use as one part of a wider access question^[2].

What this review cannot answer

This review does not test a treatment strategy in a randomised population. It cannot show that a coordinated cardio-hepatology model reduces cardiovascular events or improves liver outcomes. It also cannot establish that such a model narrows disparities. Nor can it tell a reader which medicine is right for them. Those answers need clinical trials, health-services research, and an assessment that accounts for the person's medical history and access to care.

The authors explicitly call for inclusive research and coordinated long-term care to evaluate whether the proposed strategies narrow disparities. That is a future research question, not a result already established by this review. The paper provides a useful map of the problem and a proposed direction for care, but it does not offer proof that the direction has delivered equitable outcomes^[1].

Why the connected view matters

The central message is straightforward. MASLD and cardiovascular risk interact with access to care in ways that make single-condition thinking incomplete. The authors ask clinicians and health systems to connect risk identification with fibrosis assessment. Cardiovascular prevention and access to indicated therapy belong in the same conversation. Readers should not use a review article as a personal treatment plan. If you are considering semaglutide or have questions about liver and cardiovascular risk, a qualified healthcare professional can review the evidence in the context of your own care.